Ad-hoc-Release; Berlin, February 1, 2007
MOLOGEN AG appoints new Chief Financial Officer
The Berlin-based biotechnology company MOLOGEN AG (ISIN DE0006637200) announced today that its Supervisory Board has appointed Joerg Petrass as the company’s new Chief Financial Officer effective February 1, 2007.
Chief Financial Officer Dirk Simon has left the company with effect from the close of January 31, 2007 in order to pursue new opportunities within the Healthcare industry. The decision was taken in mutual agreement.
Joerg Petrass has detailed knowledge of MOLOGEN’s business and commands, extensive expertise and long standing experience in the fields of contracting, accounting and capital market regulations. Joining MOLOGEN about five years ago, Joerg Petrass has held leading positions as deputy managing director within the financial department of the company.
"The board would like to thank Dirk Simon for his important contributions to the development of MOLOGEN. We wish him all the best in pursuing new professional opportunities", said Professor Dr Burghardt Wittig, Chief Executive Officer of MOLOGEN AG. "At the same time, we are glad about the appointment of Joerg Petrass, which guarantees a quick and smooth transition. This is of utmost importance for MOLOGEN in view of the ongoing activities to commercialize our innovate technology."
The Executive Board of MOLOGEN AG now consists of Professor Dr Burghardt Wittig, Chairman, Dr Matthias Schroff, Operations, and Joerg Petrass, Finance.
MOLOGEN AG is a listed biopharmaceutical company with headquarters in Berlin (Frankfurt Stock Exchange, Regulated Market, ISIN DE0006637200). On the basis of patented technologies (MIDGE and dSLIM), MOLOGEN develops DNA-based vaccines and therapeutic agents for the prevention and treatment of a wide range of serious illnesses.
Disclaimer concerning prognoses
Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial classification numbers, developments of the financial situation, or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for these forward-looking statements. It is not responsible for updating such information, which only represents the state of affairs on the day of publication.